Chinese pharmaceutical company Fosun Pharma, partner of German vaccine producer BioNTech's vaccine BNT162b2 announced on Wednesday it signed supply order with BioNTech Manufacturing, and will supply no less than 100 million doses of COVID-19 vaccine product for Chinese mainland in 2021.
Fosun said supplies are already in place once authorization is received.
On November 24, Fosun Pharma launched Phase II clinical trials of the vaccine in China in Taizhou and Lianshui, East China's Jiangsu Province.
On December 12, the vaccine officially obtained an emergency use authorization (EUA) from the U.S. FDA, which is suitable for people over 16 years old. The vaccine has also been authorized for use by regulatory agencies in the United Kingdom, Bahrain, Canada, Saudi Arabia and Mexico.
On December 11, the Hong Kong Special Administrative Region regulators announced that it had reached an agreement with Fosun Pharma to purchase up to 7.5 million doses of the mRNA COVID-19 vaccine (BNT162b2) jointly developed by Fosun Pharma and Germany's BioNTech. Among them, the first batch of 1 million doses of vaccine is expected to be delivered as soon as the first quarter of next year.
